ESA Biosciences, has announced that it's launched a new HPLC system designed to help expedite drug-metabolism studies and supporting medicinal chemistry efforts by electrochemically synthesising significant quantities of difficult-to-obtain metabolites from a variety of parent compounds.
At the systems' core are new, high-efficiency, high-capacity electrochemical-synthesis cells. Since the user can control the systems' oxidation capability to generate specific, desired oxidation products, they have wide utility in a variety of metabolite-generation tasks, alleviating the need to deploy precious medicinal chemistry resources to support drug-metabolism identification, while enhancing the synthesis capabilities of any laboratory.
ESA's new electrochemical synthesis systems are an ideal complement to LC-MS for ADME-Tox / DMPK and other drug-metabolism operations, because they can be used to quickly and easily generate large quantities of oxidative metabolites from parent compounds. Of particular interest to scientists evaluating the metabolic properties and toxicity of potential drugs, these systems mimic much of the oxidation capabilities of cytochrome P450, a key enzyme family that is responsible for metabolising most drugs. Drug interactions involving the cytochrome p450 system are common, and a major cause of attrition in the drug-development process. Understanding the metabolites generated by these enzymes is key to understanding a compound's metabolic fate.
ESA has designed two new synthesis cells to suite specific application needs. The 5150 cell has high capacity and is preferred for low-potential (
Product directory
